Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115698) titled 'A real-world study on the treatment of aplastic anemia with Romiplostim N01' on Dec. 30, 2025.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: Hebei Province Hospital of Chinese Medicine
Condition:
Patients with aplastic anemia (including severe AA and non-severe AA)
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2025-12-31
Target Sample Size: Romiplostim N01 treatment group:60;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=303210
Disclaimer: Curated by HT Syndication....